Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors

BACKGROUND: Panobinostat, a pan-deacetylase inhibitor, overcomes imatinib resistance in preclinical models of gastrointestinal stromal tumours (GIST). Here we determined the maximum tolerated dose (MTD) and dose-limiting toxicities (DLT) of panobinostat in combination with imatinib (IM) for treatmen...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Bauer, S, Hilger, R A, Mühlenberg, T, Grabellus, F, Nagarajah, J, Hoiczyk, M, Reichardt, A, Ahrens, M, Reichardt, P, Grunewald, S, Scheulen, M E, Pustowka, A, Bock, E, Schuler, M, Pink, D
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group 2014
Teme:
Clinical Study
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3950855/
https://ncbi.nlm.nih.gov/pubmed/24434430
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.826
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items